Study Evaluating the Safety and Efficacy of a Once-daily Dose of Tigecycline vs Ertapenem in Diabetic Foot Infections (DFI) With a Substudy in Patients With Diabetic Foot Infections Complicated by Osteomyelitis.

April 22, 2010 updated by: Wyeth is now a wholly owned subsidiary of Pfizer

A Multicenter, Randomized, Double-Blind, Comparison Study of the Safety and Efficacy of a Once-Daily Dose of Tigecycline Versus Ertapenem for the Treatment of Foot Infections in Subjects With Diabetes

The purpose of this study was to look at the safety and effectiveness of a once-daily dose of tigecycline compared to ertapenem for the treatment of diabetic foot infections. The co-primary efficacy endpoints were not met.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
1061

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Argentina
      • Buenos Aires, Argentina, 1180
      • Buenos Aires, Argentina, 1428
      • Buenos Aires, Argentina, CP 1428
      • Buenos Aires, Argentina, CP C1180 AAX
      • Ciudad Autonoma de Buenos Aires, Argentina, 1181
      • Cordoba, Argentina, 5000
      • Cordoba, Argentina, 5004
      • Cordoba, Argentina, 5016
      • Cordoba, Argentina, CP 5000
      • Cordoba, Argentina, CP 5016
      • Mendoza, Argentina, 5500
    • Buenos Aires
      • Chivilcoy, Buenos Aires, Argentina, 6620
      • Ciudadela, 3 de Febrero, Buenos Aires, Argentina, 1702
      • Ciudadela, 3 de Febrero, Buenos Aires, Argentina, CP 1702
      • La Plata, Buenos Aires, Argentina, 1072
      • La Plata, Buenos Aires, Argentina, CP 1900
      • Loma Hermosa, Buenos Aires, Argentina, 1657
      • Loma Hermosa, Buenos Aires, Argentina, CP 1657
      • Merlo, Buenos Aires, Argentina, 1722
      • Moron, Buenos Aires, Argentina, 1072
    • Entre Rios
      • Parana, Entre Rios, Argentina, 3100
    • Entre Ríos
      • Paraná, Entre Ríos, Argentina, CP 3100
    • Mendoza
      • Tunuyan, Mendoza, Argentina, 5560
    • Provincia de Buenos Aires
      • La Plata, Provincia de Buenos Aires, Argentina, 1900
      • Mar del Plata, Provincia de Buenos Aires, Argentina, 7602
    • Provincia de Tucuman
      • San Miguel de Tucuman, Provincia de Tucuman, Argentina, 4000
    • Santa Fe
      • Rosario, Santa Fe, Argentina, 2000
  • Australia
    • Victoria
      • Melbourne, Victoria, Australia, 3050
      • Melbourne, Victoria, Australia, 3128
  • Austria
      • Wien, Austria, 1100
  • Belgium
      • Bornem, Belgium, 2880
      • Brussel, Belgium, 1090
      • Bruxelles, Belgium, 1070
      • Bruxelles, Belgium, 1080
      • Pellenberg, Belgium, 3212
  • Brazil
      • Rio de Janeiro, Brazil, 20211-340
      • Sao Paulo, Brazil, 05422-970
  • Canada
    • British Columbia
      • Vancouver, British Columbia, Canada, V6Z 1Y6
    • Manitoba
      • Winnipeg, Manitoba, Canada, R3A 1R9
    • Ontario
      • Hamilton, Ontario, Canada, L8V 1C3
      • Ottawa, Ontario, Canada, K1H 8L6
    • Quebec
      • Chicoutimi, Quebec, Canada, G7H 5H6
      • Montreal, Quebec, Canada, H3T 1E2
      • Sherbrooke, Quebec, Canada, J1H 5N4
      • Trois-Rivieres, Quebec, Canada, G8Z 3R9
  • Chile
      • Santiago, Chile
      • Valdivia, Chile
  • China
      • Beijing, China, 100730
      • Beijing, China, 100101
      • Guangzhou, China, 510120
      • Tianjin, China, 300070
    • Heilongjiang
      • Harbin, Heilongjiang, China, 150086
  • Colombia
      • Bogota, Colombia
      • Bogota, Colombia, NAP
  • Croatia
      • Zadar, Croatia, 23 000
      • Zagreb, Croatia, 10000
      • Zagreb, Croatia, 10 000
  • Denmark
      • Odense, Denmark, 5000
  • Estonia
      • Tallinn, Estonia, 13419
      • Tartu, Estonia, 51014
      • Tartu, Estonia, 50410
    • Ida Virumaa
      • Kohtla Jarve, Ida Virumaa, Estonia, 30322
  • Finland
      • Kuopio, Finland, 70210
      • Turku, Finland, 20520
  • France
      • Strasbourg, France, 67000
      • Tourcoing, France, 59200
  • Germany
    • Hessen
      • Giessen, Hessen, Germany, 35392
    • North Rhine-Westphalia
      • Bochum, North Rhine-Westphalia, Germany, 44789
      • Gelsenkirchen, North Rhine-Westphalia, Germany, 45891
      • Rheine, North Rhine-Westphalia, Germany, 48431
    • Northrhien-Westphalia
      • Muenster, Northrhien-Westphalia, Germany, 48129
  • Greece
      • Athens, Greece, 106 76
      • Holargos, Athens, Greece, 11527
      • Rio-Patras, Greece, 265 04
  • Hungary
      • Budapest, Hungary, 1082
      • Budapest, Hungary, 1076
      • Budapest, Hungary, H-1027
      • Debrecen, Hungary, 4012
      • Gyor, Hungary, 9024
      • Kistarcsa, Hungary, 2143
      • Szekesfehervar, Hungary, 8000
  • India
    • Gujarat
      • Baroda, Gujarat, India, 390001
    • Karnataka
      • Bangalore, Karnataka, India, 560002
    • Maharashtra
      • Pune, Maharashtra, India, 411001
    • Rajasthan
      • Jaipur, Rajasthan, India, 302001
  • Italy
      • Abano terme (PD), Italy, 35031
      • Pisa, Italy, 56124
      • Rome, Italy, 133
  • Korea, Republic of
      • Gyeonggi-do, Korea, Republic of, 425-801
      • Seoul, Korea, Republic of, 138-736
      • Seoul, Korea, Republic of, 135-710
      • Seoul, Korea, Republic of, 136-075
  • Latvia
      • Liepaja, Latvia, 3401
      • Riga, Latvia, 1002
      • Riga, Latvia, 1038
      • Riga, Latvia, LV-1038
      • Riga, Latvia, LV-1001
      • Riga, Latvia, 1001
  • Lithuania
      • Kaunas, Lithuania, 47144
      • Kaunas, Lithuania, 50009
      • Kaunas, Lithuania, LT-50009
      • Klaipeda, Lithuania, 92288
      • Panevezys, Lithuania, 35144
      • Siauliai, Lithuania, 76231
      • Vilnius, Lithuania, 10207
      • Vilnius, Lithuania, LT-10207
  • Mexico
      • Durango, Mexico, 34000
      • Mendoza, Mexico, CP 5500
      • San Luis Potosi, Mexico, 78210
      • San Luis Potosi, Mexico, CP 78210
      • Santa Fe, Mexico, CP 2000
      • Veracruz, Mexico, 91910
    • Guadalajara
      • Colonia El Ritiro, Guadalajara, Mexico, 44280
    • Jalisco
      • Guadalajara, Jalisco, Mexico, 44260
    • Sonora
      • Hermosillo, Sonora, Mexico, 83190
  • Panama
      • Panama, Panama, 907
  • Peru
      • Lima, Peru, Lima 11
      • Lima, Peru, Lima 31
  • Poland
      • Bielsko-Biala, Poland, 43-300
      • Cieszyn, Poland, 43-400
      • Gdansk, Poland, 80-211
      • Lodz, Poland, 91-425
      • Warsaw, Poland, 02-097
      • Wroclaw, Poland, 50-326
  • Portugal
      • Lisboa, Portugal, 1169-050
      • Lisbon, Portugal, 1495-005
  • Romania
      • Bacau, Romania, 600114
      • Bucharest, Romania, 20475
      • Cluj-Napoca, Romania, 400006
      • Lasi, Romania, 700111
  • Russian Federation
      • Chelyabinsk, Russian Federation, 454 021
      • Ekaterinburg, Russian Federation, 620109
      • Kemerovo, Russian Federation, 650061
      • Moscow, Russian Federation, 111020
      • Moscow, Russian Federation, 129110
      • Moscow, Russian Federation, 127299
      • Moscow, Russian Federation, 127486
      • Moscow, Russian Federation, 129327
      • Moscow, Russian Federation, 113152
      • Nizhniy Novgorod, Russian Federation, 603005
      • Nizhny Novgorod, Russian Federation, 603076
      • Novosibirsk, Russian Federation, 630117
      • Omsk, Russian Federation, 644021
      • Smolensk, Russian Federation, 214019
      • St. Petersburg, Russian Federation, 196247
      • St. Petersburg, Russian Federation, 198095
      • Yaroslavl, Russian Federation
  • Slovakia
      • Banska Bystrica, Slovakia, 975 17
      • Banska.Bysterica, Slovakia, 97517
      • Bratislava, Slovakia, 813 69
      • Lubochna, Slovakia, 034 91
      • Martin, Slovakia, 036 59
      • Nitra, Slovakia, 949 01
      • Nove Zamky, Slovakia, 9401
  • South Africa
    • Eastern Cape
      • Port Elizabeth, Eastern Cape, South Africa, 6014
    • Gauteng
      • Benoni, Gauteng, South Africa, 1501
      • Pretoria, Gauteng, South Africa, 84
  • Spain
      • Barcelona, Spain, 8907
      • Getafe Madrid, Spain, 28905
      • Granada, Spain, 18012
      • Madrid, Spain, 28007
      • Palma de Mallorca, Spain, 7198
  • Sweden
      • Copenhagen, Sweden, 2400
      • Huddinge, Sweden, 141 86
      • Uppsala, Sweden, 751 85
  • Switzerland
      • Basel, Switzerland, CH 4031
      • Geneva, Switzerland, CH 1211
  • Taiwan
      • Tainan, Taiwan
      • Taoyuan Hsien, Taiwan
  • Turkey
      • Adana, Turkey, 1330
      • Capa-Istanbul, Turkey, 34390
      • Istanbul, Turkey, 34303
  • Ukraine
      • Cherkassy, Ukraine, 18009
      • Dnepropetrovsk, Ukraine, 49001
      • Kiev, Ukraine, 2125
      • Kyiv, Ukraine, 02175
      • Kyiv, Ukraine, 2175
      • Lviv, Ukraine, 79010
      • Vinnytsia, Ukraine, 21010
      • Zaporozhye, Ukraine, 69600
  • United Kingdom
      • Birmingham, United Kingdom, B95SS
      • London, United Kingdom, SE5 9RS
      • Oxford, United Kingdom, OX3 7LD
    • Lanarkshire
      • Wishaw, Lanarkshire, United Kingdom, ML2 0DP
    • West Midlands
      • Birmingham, West Midlands, United Kingdom, B29 6JD
  • United States
    • California
      • Los Angeles, California, United States, 90010
      • Los Angeles, California, United States, 91342
      • Northridge, California, United States, 91326
      • San Francisco, California, United States, 94115
      • Sylmar, California, United States, 91342
      • Torrance, California, United States, 90502
    • Florida
      • Orlando, Florida, United States, 32806
      • Orlando, Florida, United States, 32801
      • Pensacola, Florida, United States, 32501
      • West Palm Beach, Florida, United States, 33407
    • Hawaii
      • Honolulu, Hawaii, United States, 96814
    • Illinois
      • Chicago, Illinois, United States, 60637
      • Evanston, Illinois, United States, 60201
      • North Chicago, Illinois, United States, 60064
      • Springfield, Illinois, United States, 62701
      • Springfield, Illinois, United States, 62791
    • Maryland
      • Baltimore, Maryland, United States, 21224
    • Massachusetts
      • Boston, Massachusetts, United States, 02215
    • New Jersey
      • Somers Point, New Jersey, United States, 08244
    • North Carolina
      • Winston-Salem, North Carolina, United States, 27103
    • Ohio
      • Lima, Ohio, United States, 45801
      • Toledo, Ohio, United States, 43614
    • Pennsylvania
      • West Reading, Pennsylvania, United States, 19610
    • South Carolina
      • Columbia, South Carolina, United States, 29203
    • Texas
      • Dallas, Texas, United States, 75203
      • San Antonio, Texas, United States, 78229

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Main inclusion criteria:

  • Men and women aged 18 or older with diabetes and a qualifying foot infection. People with evidence of a diabetic foot infection with osteomyelitis may qualify for the osteomyelitis substudy arm.

Main exclusion criteria:

  • People with additional significant disease, infection with resistant pathogens, contraindication, or hypersensitivity to any test article or related antibiotic.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Active Comparator: A
Drug: Tigecycline
150 mg Tigecycline once-daily IV infusion for up to 28 days, or 42 days for the substudy wth osteomyelitis
Active Comparator: B
Drug: Ertapenem
Ertapenem 1g IV infusion every 24 hours +/- vancomycin depending on culture results and at the discretion of investigator (for coverage of Methicillin-resistant Staphylococcus aureus (MRSA), coagulase-negative staphylococci (CNS) or enterococci coverage).

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Number of Patients With Clinical Response of Cure Vs. Failure.
Time Frame: Test of cure visit (TOC): Assessed at least 12 days post last dose
Cure: Recovery so no added antibiotic therapy. Failure: Added antibiotic therapy for no response or worsening after improvement, new purulence, >120% doses, non-routine surgical treatment or death related to Diabetic Foot Infections (DFI) > 48 hrs.
Test of cure visit (TOC): Assessed at least 12 days post last dose
Number of Patients With Clinical Response of Cure Vs. Failure/Indeterminate.
Time Frame: Test of cure visit (TOC): Assessed at least 12 days post last dose
Cure: Recovery so no added antibiotic therapy. Failure: Added antibiotic therapy for no response or worsening after improvement, new purulence, >120% doses, non-routine surgical treatment or death related to DFI > 48 hrs. Indeterminate: Lost to follow-up, death<48 hours or noninfection related.
Test of cure visit (TOC): Assessed at least 12 days post last dose

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Number of Patients With Clinical Response of Cure Vs. Failure Assessed at Least 25 - 27 Weeks Post Last Dose.
Time Frame: Test of cure visit (TOC): Assessed at least 25 - 27 weeks post last dose
Cure: Recovery so no added antibiotic therapy. Failure: Added antibiotic therapy for no response or worsening after improvement, new purulence, >120% doses, non-routine surgical treatment or death related to DFI > 48 hrs.
Test of cure visit (TOC): Assessed at least 25 - 27 weeks post last dose
Number of Patients With Clinical Response of Cure Vs. Failure/Indeterminate Assessed at Least 25 - 27 Weeks Post Last Dose.
Time Frame: Test of cure visit (TOC): Assessed at least 25 - 27 weeks post last dose
Cure: Recovery so no added antibiotic therapy. Failure: Added antibiotic therapy for no response or worsening after improvement, new purulence, >120% doses, non-routine surgical treatment or death related to DFI > 48 hrs. Indeterminate: Lost to follow-up, death<48 hours or noninfection related.
Test of cure visit (TOC): Assessed at least 25 - 27 weeks post last dose
Number of Patients With Microbiologic Response of Eradication.
Time Frame: Test of cure visit (TOC): Assessed at least 12 days post last dose
Eradication defined as: no pathogen is present in the repeat culture from the original site of infection, or a clinical response of the cure precludes the availability of a specimen for culture.
Test of cure visit (TOC): Assessed at least 12 days post last dose

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Wyeth is now a wholly owned subsidiary of Pfizer

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Trial Manager, For Australia, medinfo@wyeth.com
  • Principal Investigator: Trial Manager, For Austria, WPVIMED@wyeth.com
  • Principal Investigator: Trial Manager, For Greece, decresg@wyeth.com
  • Principal Investigator: Trial Manager, For Poland, WPWZMED@wyeth.com
  • Principal Investigator: Trial Manager, For Romania, WVPIMED@wyeth.com
  • Principal Investigator: Trial Manager, For Spain, infomed@wyeth.com
  • Principal Investigator: Trial Manager, For South Africa, ZAFinfo@wyeth.com
  • Principal Investigator: Trial Manager, For Switzerland, med@wyeth.com
  • Principal Investigator: Trial Manager, For Turkey, Erisc@wyeth.com
  • Principal Investigator: Trial Manager, For Brazil, xavierl@wyeth.com
  • Principal Investigator: Trial manager, For Hungary, WPBUMED@wyeth.com
  • Principal Investigator: Trial Manager, For Mexico, gomezzlj@wyeth.com
  • Principal Investigator: Trial Manager, For Canada, clintrialparticipation@wyeth.com
  • Principal Investigator: Trial Manager, For Croatia, WPBUMED@wyeth.com
  • Principal Investigator: Trial Manager, For Latvia, WPVIMED@wyeth.com
  • Principal Investigator: Trial Manager, For Lithuania, WPVIMED@wyeth.com
  • Principal Investigator: Trial Manager, For Argentina, Scheima@wyeth.com
  • Principal Investigator: Trial Manager, For Chile, scheima@wyeth.com
  • Principal Investigator: Trial Manager, For Sweden, MedInfoNord@wyeth.com
  • Principal Investigator: Trial Manager, For Denmark, medinfonord@wyeth.com
  • Principal Investigator: Trial Manager, For Estonia, WVPMED@wyeth.com
  • Principal Investigator: Trial Manager, For Finland, MedInfoNord@wyeth.com
  • Principal Investigator: Trial Manager, For UK/Great Britian: ukmedinfo@wyeth.com
  • Principal Investigator: Trial Manager, For Russia, WVPIMED@wyeth.com
  • Principal Investigator: Trial Manager, For Slovakia, DIS-WP-BV-EUBV01-Medical@wyeth.com
  • Principal Investigator: Trial Manager, For Ukraine, WVPIMED@wyeth.com

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
January 1, 2007

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
March 1, 2009

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
March 1, 2009

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
August 17, 2006

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 17, 2006

First Posted (Estimate)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
August 21, 2006

Study Record Updates

Last Update Posted (Estimate)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
April 28, 2010

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
April 22, 2010

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
April 1, 2010

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 3074K5-319

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Diabetic Foot

Clinical Trials on Tigecycline

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings